Skip to main content
Erschienen in: Tumor Biology 12/2015

01.12.2015 | Research Article

Antitumor effects evaluation of a novel porphyrin derivative in photodynamic therapy

verfasst von: Jian-Wei Li, Zhong-Ming Wu, Davor Magetic, Li-Jun Zhang, Zhi-Long Chen

Erschienen in: Tumor Biology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

In this paper, the antitumor activity of a novel porphyrin-based photosensitizer 5,10,15,20-tetrakis[(5-diethylamino)pentyl] porphyrin (TDPP) was reported in vitro and in vivo. The photophysical and cellular properties of TDPP were investigated. The singlet oxygen generation quantum yield of TDPP was detected; it showed a high singlet oxygen quantum yield of 0.52. The intracellular distribution of photosensitizer was detected with laser scanning confocal microscopy. The efficiency of TDPP-photodynamic therapy (PDT) in vitro was analyzed by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay and in situ trypan blue exclusion test. Treated with a 630-nm laser, TDPP can kill cultured human esophageal cancer cell line (Eca-109) cells and reduce the growth of Eca-109 xenograft tumors significantly in BABL/c nude mice. And histopathological study was also used to confirm the antitumor effect. It has the perspective to be developed as a new antitumor drug in photodynamic therapy and deserves further investigation.
Literatur
1.
9.
Zurück zum Zitat Zhang LJ, Bian J, Bao LL, Chen HF, Yan YJ, Wang L, et al. Photosensitizing effectiveness of a novel chlorin-based photosensitizer for photodynamic therapy in vitro and in vivo. J Cancer Res Clin Oncol. 2014;140(9):1527–36. doi:10.1007/s00432-014-1717-0.CrossRefPubMed Zhang LJ, Bian J, Bao LL, Chen HF, Yan YJ, Wang L, et al. Photosensitizing effectiveness of a novel chlorin-based photosensitizer for photodynamic therapy in vitro and in vivo. J Cancer Res Clin Oncol. 2014;140(9):1527–36. doi:10.​1007/​s00432-014-1717-0.CrossRefPubMed
10.
Zurück zum Zitat Yan YJ, Zheng MZ, Chen ZL, Yu XH, Yang XX, Ding ZL, et al. Studies on preparation and photodynamic mechanism of chlorin p 6–13,15-N-(cyclohexyl)cycloimide (Chlorin-H) and its antitumor effect for photodynamic therapy in vitro and in vivo. Bioorg Med Chem. 2010;18(17):6282–91. doi:10.1016/j.bmc.2010.07.027.CrossRefPubMed Yan YJ, Zheng MZ, Chen ZL, Yu XH, Yang XX, Ding ZL, et al. Studies on preparation and photodynamic mechanism of chlorin p 6–13,15-N-(cyclohexyl)cycloimide (Chlorin-H) and its antitumor effect for photodynamic therapy in vitro and in vivo. Bioorg Med Chem. 2010;18(17):6282–91. doi:10.​1016/​j.​bmc.​2010.​07.​027.CrossRefPubMed
12.
Zurück zum Zitat Kempa M, Kozub P, Kimball J, Rojkiewicz M, Kus P, Gryczynski Z, et al. Physicochemical properties of potential porphyrin photosensitizers for photodynamic therapy. Spectrochim Acta A Mol Biomol Spectrosc. 2015;146:249–54. doi:10.1016/j.saa.2015.03.076.CrossRefPubMed Kempa M, Kozub P, Kimball J, Rojkiewicz M, Kus P, Gryczynski Z, et al. Physicochemical properties of potential porphyrin photosensitizers for photodynamic therapy. Spectrochim Acta A Mol Biomol Spectrosc. 2015;146:249–54. doi:10.​1016/​j.​saa.​2015.​03.​076.CrossRefPubMed
13.
Zurück zum Zitat Zenkevich EI. Structural dynamics and relaxation processes with participation of excited singlet and triplet states in sterically hindered porphyrins and their chemical dimers. Macroheterocycles. 2014;7(2):103–21. doi:10.6060/Mhc140597z.CrossRef Zenkevich EI. Structural dynamics and relaxation processes with participation of excited singlet and triplet states in sterically hindered porphyrins and their chemical dimers. Macroheterocycles. 2014;7(2):103–21. doi:10.​6060/​Mhc140597z.CrossRef
14.
Zurück zum Zitat Serra AC, Pineiro M, Rocha Gonsalves AM, Abrantes M, Laranjo M, Santos AC, et al. Halogen atom effect on photophysical and photodynamic characteristics of derivatives of 5,10,15,20-tetrakis(3-hydroxyphenyl)porphyrin. J Photochem Photobiol B Biol. 2008;92(1):59–65. doi:10.1016/j.jphotobiol.2008.04.006.CrossRef Serra AC, Pineiro M, Rocha Gonsalves AM, Abrantes M, Laranjo M, Santos AC, et al. Halogen atom effect on photophysical and photodynamic characteristics of derivatives of 5,10,15,20-tetrakis(3-hydroxyphenyl)porphyrin. J Photochem Photobiol B Biol. 2008;92(1):59–65. doi:10.​1016/​j.​jphotobiol.​2008.​04.​006.CrossRef
16.
Zurück zum Zitat Milanesio ME, Moran FS, Yslas EI, Alvarez MG, Rivarola V, Durantini EN. Synthesis and biological evaluation of methoxyphenyl porphyrin derivatives as potential photodynamic agents. Bioorg Med Chem. 2001;9(8):1943–9.CrossRefPubMed Milanesio ME, Moran FS, Yslas EI, Alvarez MG, Rivarola V, Durantini EN. Synthesis and biological evaluation of methoxyphenyl porphyrin derivatives as potential photodynamic agents. Bioorg Med Chem. 2001;9(8):1943–9.CrossRefPubMed
17.
Zurück zum Zitat Juarranz A, Jaen P, Sanz-Rodriguez F, Cuevas J, Gonzalez S. Photodynamic therapy of cancer. Basic principles and applications. Clin Translat Oncology Off Public Fed Spanish Oncol Soc National Cancer Inst of Mexico. 2008;10(3):148–54. Juarranz A, Jaen P, Sanz-Rodriguez F, Cuevas J, Gonzalez S. Photodynamic therapy of cancer. Basic principles and applications. Clin Translat Oncology Off Public Fed Spanish Oncol Soc National Cancer Inst of Mexico. 2008;10(3):148–54.
18.
Zurück zum Zitat Redmond RW, Gamlin JN. A compilation of singlet oxygen yields from biologically relevant molecules. Photochem Photobiol. 1999;70(4):391–475.CrossRefPubMed Redmond RW, Gamlin JN. A compilation of singlet oxygen yields from biologically relevant molecules. Photochem Photobiol. 1999;70(4):391–475.CrossRefPubMed
19.
Zurück zum Zitat Hampton JA, Selman SH. Mechanisms of cell killing in photodynamic therapy using a novel in vivo drug/in vitro light culture system. Photochem Photobiol. 1992;56(2):235–43.CrossRefPubMed Hampton JA, Selman SH. Mechanisms of cell killing in photodynamic therapy using a novel in vivo drug/in vitro light culture system. Photochem Photobiol. 1992;56(2):235–43.CrossRefPubMed
20.
Zurück zum Zitat Stockert JC, Canete M, Juarranz A, Villanueva A, Horobin RW, Borrell JI, et al. Porphycenes: facts and prospects in photodynamic therapy of cancer. Curr Med Chem. 2007;14(9):997–1026.CrossRefPubMed Stockert JC, Canete M, Juarranz A, Villanueva A, Horobin RW, Borrell JI, et al. Porphycenes: facts and prospects in photodynamic therapy of cancer. Curr Med Chem. 2007;14(9):997–1026.CrossRefPubMed
21.
Zurück zum Zitat van Hillegersberg R, Kort WJ, Wilson JH. Current status of photodynamic therapy in oncology. Drugs. 1994;48(4):510–27.CrossRefPubMed van Hillegersberg R, Kort WJ, Wilson JH. Current status of photodynamic therapy in oncology. Drugs. 1994;48(4):510–27.CrossRefPubMed
22.
Metadaten
Titel
Antitumor effects evaluation of a novel porphyrin derivative in photodynamic therapy
verfasst von
Jian-Wei Li
Zhong-Ming Wu
Davor Magetic
Li-Jun Zhang
Zhi-Long Chen
Publikationsdatum
01.12.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3745-z

Weitere Artikel der Ausgabe 12/2015

Tumor Biology 12/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.